Natalie Callander, MD
Hematology · Madison, WINPI 1649247339
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AstraZeneca at 54.0% of the total. Reporting peaked in 2024 at $5,479 and has fallen 76.8% since, to $1,273 in 2025.
Across 59 payments — averaging $179.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- National Marrow Donor Program$3K
- Taiho Oncology, Inc.$777
- Johnson & Johnson$417
- Bristol Myers Squibb$146
- Pfizer$94
- plus $152 from 3 others
Across 448 payments — averaging $15,170 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2.3M
- Amgen$1.2M
- Bristol Myers Squibb$1.1M
- Janssen Research & Development, LLC$457K
- Novartis$427K
- Beigene, Ltd.$304K
- plus $957K from 9 others
What the payments were for
- Consulting fees$4,10039%
- Speaking & faculty fees$1,12011%
- Travel & lodging$3,72435%
- Food & beverage$1,65116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $5,717 |
| National Marrow Donor Program | 11 | $3,292 |
| Taiho Oncology, Inc. | 12 | $777 |
| Johnson & Johnson | 5 | $417 |
| Bristol Myers Squibb | 2 | $146 |
| Pfizer | 2 | $94 |
| Adaptive Biotechnologies Corporation | 1 | $90 |
| Sanofi | 1 | $44 |
| Legend Biotech USA Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 117 | $1,943,225 |
| Lenalidomide | 71 | $961,758 |
| PomalystPomalidomide | 45 | $902,666 |
| BrukinsaZanubrutinib | 16 | $239,141 |
| VenclextaVenetoclax | 21 | $102,405 |
| EliquisApixaban | 36 | $35,612 |
| OxycontinOxycodone Hcl | 36 | $12,011 |
| CreonLipase/Protease/Amylase | 13 | $9,052 |
| Acyclovir | 337 | $5,451 |
| Morphine Sulfate ErMorphine Sulfate | 44 | $2,442 |
| Oxycodone Hcl | 45 | $1,757 |
| Colestipol Hcl | 16 | $1,108 |
| Potassium Chloride | 22 | $900 |
| Pantoprazole Sodium | 31 | $898 |
| Dexamethasone | 62 | $753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $146 | $1,943,225117 claims |
| PfizerEliquis | $94 | $35,61236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other hematology in Madison
- Hongtao LiuMadison$29K
- John SheehanMadison$25K
- Julie ChangMadison$17K
- David YangMadison$136
- Savanah GisrielMadison$52
- Kim DittusMadison$23
- Bradford SchwartzMadison$0
- Eliot WilliamsMadison$0
- Christopher FletcherMadison$0
- Michael DeiningerMilwaukee$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.